AOD-9604
AOD-9604 and LAT8881 are names on the same GSRS record. A 53-person oral trial missed its pain endpoint (NCT03865953; claims checked 24 August 2026). The pain test did not show that the drug beat placebo. It was not a weight-loss test. Both points matter. Lateral Pharma sponsored it. The opened sources publish no human weight-loss result. The EU field remains unclear.
Is LAT8881 the same compound as AOD-9604?
Yes. The US FDA/NCATS GSRS record for UNII 7UP768IP4M lists both names (GSRS; claims checked 24 August 2026). It also lists LAT-8881, AOD9604, and LAT8881. The names lead to one set of sources. The IDs make that link clear. That is the point of the ID check.
What did the posted human trial measure?
NCT03865953 compared oral LAT8881 with placebo in 53 people with nerve pain. Each treatment period lasted four weeks. Lateral Pharma sponsored the trial.
| Primary pain result | LAT8881 | Placebo | Net result |
|---|---|---|---|
| Mean change | -0.87 | -0.74 | -0.14 (95% CI -0.76 to 0.49; p=0.67) |
The primary endpoint did not show a significant difference. No participant died or had a serious adverse event. Upper respiratory infection affected 3 of 51 people in each group. Headache affected 2 of 51 with LAT8881 and 4 of 51 with placebo (NCT03865953; claims checked 24 August 2026).
What did the six-trial safety paper report?
The paper summarised six randomised placebo-controlled trials (DOI 10.4021/jem157w). It reported no related withdrawal or serious adverse event. It reported no detected anti-AOD-9604 antibodies. Metabolic Pharmaceuticals funded all six trials (claims checked 22 August 2026).
Did human studies publish a weight-loss result?
No published human weight-loss result was found in the opened sources and exact-name searches (checked 22 August 2026). The safety paper names two large obesity trials. It does not publish their efficacy results.
What is the recorded EU status?
The EU field remains unclear. The signed EMA search found no central-register row for AOD-9604, AOD9604, or hGH Fragment 176-191 on 22 August 2026. That search does not cover every national register.
When was AOD-9604 first recorded?
No sourced first-observed month is established in this page's source set (checked 24 August 2026). The field remains empty instead of estimated.
What names and identifiers belong to this record?
GSRS uses display name LAT-8881. It lists AOD-9604, AOD9604, and LAT8881. The record carries UNII 7UP768IP4M and CAS 221231-10-3 (claims checked 24 August 2026).
What does this register entry cover?
This entry keeps identity, human evidence, EU status, and vial evidence apart. The full AOD-9604 guide covers animal studies and product evidence. A vial can only be assessed from evidence about that vial.